 Method
 Open access
 Published:
ReMixT: clonespecific genomic structure estimation in cancer
Genome Biology volume 18, Article number: 140 (2017)
Abstract
Somatic evolution of malignant cells produces tumors composed of multiple clonal populations, distinguished in part by rearrangements and copy number changes affecting chromosomal segments. Whole genome sequencing mixes the signals of sampled populations, diluting the signals of clonespecific aberrations, and complicating estimation of clonespecific genotypes. We introduce ReMixT, a method to unmix tumor and contaminating normal signals and jointly predict mixture proportions, clonespecific segment copy number, and clone specificity of breakpoints. ReMixT is free, opensource software and is available at http://bitbucket.org/dranew/remixt.
Background
Chromosomal rearrangements pattern the genomes of cancer cells. Owing to various forms of DNA repair deficiency, such structural variations accumulate on cell division, leading to genome instability in the life histories of cancer cells. Coupled with evolutionary selection and clonal expansion, genomic instability and consequent segmental aneuploidies mark expanded cell populations within a tumour, forming important components of their genotypes. Within each tumour, branched evolution produces mixed populations of tumour cells with ancestrally related, but divergent chromosomal structures.
Accurate detection and quantification of genomic structural changes in a population of cancer cells as measured by bulk, whole genome sequencing (WGS) remains a significant computational challenge. The process of DNA extraction from a tumour sample pools and admixes molecules from the input material without labelling the assignment of DNA to its parent cell. The resulting sequencing data represent a randomly sampled subset of DNA fragments from the admixed pool, leaving the problem of unmixing the structural rearrangements which mark the constituent clones in the input material. The key difficulty of the problem is that the admixed pool dilutes the signal of genomic rearrangements and copy number alterations in the data, often to a level approaching that of the experimental noise.
Rearrangements and copy number changes are intrinsically linked, with unbalanced rearrangements producing changes in copy number, and loss or gain of rearranged chromosomes resulting in segmentspecific copy changes. Rearrangement breakpoints representing tumourspecific adjacencies can be predicted with reasonable accuracy from WGS data using a variety of tools [1–4]. However, existing methods for copy number analysis do not consider tumourspecific adjacencies, and instead model segments as adjacent only if they are adjacent in the reference genome [5–9]. This results in only partial ability to leverage the spatially correlated nature of the data to borrow statistical strength.
We propose that breakpoints provide the potential for a more comprehensive model of genome structure. Knowledge of longrange connectivity between segments of a cancer genome provides the opportunity to simultaneously analyse breakpoints and copy number in a unified model and to reconstruct the true genomic topology. Integrating both copy number and breakpoints also provides additional information about each breakpoint: whether the breakpoint is real or a false positive, the prevalence of the breakpoint in the clone mixture, and the number of chromosomes harbouring the breakpoint per clone. A natural hypothesis then emerges: a comprehensive model of genome structure will improve both copy number inference and biological interpretation through reconstructed tumour genomes.
Some progress has been made on more comprehensive modelling of genome structure in tumour clones. Mahmoody et al. [10] propose an algorithm to infer missing adjacencies in a mixture of rearranged tumour genomes; however, they do not model copy number. Zerbino et al. [11] propose a framework for sampling from the rearrangement history of tumour genomes. Oesper et al. [12] propose PREGO, a method for inferring the copy number of segments and breakpoints using a genome graphbased approach, though they do not model normal contamination or tumour heterogeneity, limiting applicability of their method to real tumour data. More recently, Li et al. [13] formulate a Markov random field model of allelespecific copy number change and apply their method, Weaver, to samples harbouring a single tumour clone and contaminating normal cells.
We propose ReMixT, a method for jointly inferring clone mixture proportions, clone and allelespecific segment copy numbers, and clonespecific breakpoint copy number from WGS data. We formulate the problem as a posterior inference problem on a probabilistic graphical model. Our model captures the spatial correlation both between segments that are adjacent in the reference genome in addition to correlations between segments adjacent in the tumour genome as nominated by predicted breakpoints. We describe an algorithmic solution using structured variational inference. Importantly, our algorithm is similar in complexity to a breakpointnaive hidden Markov model (HMM) of segment copy number. We leverage haplotype blocks to more accurately measure allelespecific read counts and infer allelespecific copy number for each clone.
We assert that joint inference of all three features of genome sequencing described above will result in more accurate prediction compared to independent inference. Knowledge of rearrangement breakpoints will prevent the smoothing over of copy number changes produced by true rearrangements. Incorrect smoothing of highly rearranged chromosomes may have detrimental effects on the estimation of mixing proportions and variance parameters, as the model would be forced to compensate for an unexpected increase or decrease in read depth across the smoothed chromosomes. Finally, post hoc prediction of rearrangement breakpoint copy number based on segment copy number may fail if the exact locations of associated copy number transitions are not identified, particularly for rearrangements present in a minor fraction of clones.
We show using simulations that a more complete model of genome structure that includes breakpoint information results in improved inference of mixture proportion and segment copy number over an otherwise equivalent HMM combined with post hoc annotation. Performance improvements are most dramatic when the proportion of one clone is small. We benchmark ReMixT against TITAN [5], THetA2 [14], Battenberg [8], and CloneHD [7] using a novel framework for generating realistic partially simulated WGS datasets from an existing WGS dataset. As further validation, we applied ReMixT to four primary tumour samples from a patient with highgrade serous ovarian cancer (HGSOvCa) and performed single cell breakpoint sequencing on a subset of the clonespecific breakpoints. Next we applied ReMixT to a primary breast cancer sample and its derived mouse xenograft samples, recapitulating previously described [15] clonal dynamics identified using deep sequencing of single nucleotide variants (SNVs). Finally, we analysed two HGSOvCa cell lines, providing examples of how ReMixTpredicted clonespecific breakpoints can phase disparate subclonal genomic regions into partial tumour chromosomes towards fully reconstructing clonespecific cancer genomes.
Results
The ReMixT model of genome structure
We consider the problem of predicting segment and breakpoint copy number given WGS data from tumour and matched normal samples. Assume as input a set of alignments of uniquely mapped concordant reads and a set of putative breakpoints predicted from discordant reads. Given N segments indexed by n, n∈{1…N}; K breakpoints indexed by k, k∈{1…K}; and assuming M clones indexed by m, m∈{1…M}, we aim to predict the following:

1.
Mixture proportions of tumour clones and normal cells ρ _{ m }

2.
Clone and allelespecific copy numbers of genomic segments c _{ nm }

3.
Clonespecific copy number of rearrangement breakpoints b _{ km }
Data preprocessing
Preprocessing of tumour WGS data produces measured total and allelespecific read counts for a set of genomic segments in addition to tumourspecific adjacencies between those segments. First, the genome is partitioned into regular length segments, with segments containing the breakends of input breakpoints further partitioned such that each breakend coincides with a segment boundary. Total read counts are obtained by counting the number of uniquely aligned pairedend reads fully contained within each segment. Next, haplotype blocks are predicted from single nucleotide polymorphisms (SNPs) using shapeit2 [16] and a 1000 Genomes reference panel. Reads containing heterozygous SNPs are assigned to haplotype blocks, and haplotype block counts are aggregated within segments, resulting in persegment allelespecific read counts. GC and mappability biases contribute significant variance to segment read counts. We use a positionspecific model [17] to calculate a biasadjusted effective length for each segment, where segments with shorter effective lengths are statistically less well represented by read counts. For visualization purposes, we calculate raw major and minor copy numbers for each segment from observed depths and allele ratios and inferred normal and tumour depth. Additional details are provided in Additional file 1: Sections 1.1 and 1.2.
Probabilistic model
We propose a probabilistic model of genome structure and a structured variational inference algorithm for calculating the optimal clone mixture and segment and breakpoint copy number (Fig. 1). Below we focus on a model of total copy number and defer the details of the allelespecific model and modelling of outliers to Additional file 1: Section 1.3. Let p(xc,h,l,θ) be the likelihood of observed total read count x given per clone segment copy number c, segment length l, global likelihood parameters θ, and per clone haploid read depths h. The haploid read depths encode both the mixture and depth of sequencing and are specified as reads per nucleotide for a single copy of a segment. The expected read count μ _{ n } of segment n is a linear combination of the segment length, clonespecific copy number, and clonespecific haploid read depth, summed over clones (Eq. 1):
A reasonable starting point is to assume read counts are Poisson distributed [18] (x _{ n }∼ Pois(μ _{ n })); however, we show in Additional file 1: Section 1.2.3, that a twocomponent negative binomial mixture provides a significantly better fit to real data.
Let p(C,BO,λ) be the joint probability of segment and breakpoint copy number (C and B respectively) given breakend orientations O. We assume the copy numbers of a sequence of segments have the Markov propertygiven breakpoint copy number, and represent the resulting chain structure as a product of unnormalized transition factors^{1}. A breakpoint with breakend interposed between two segments will result in a copy number transition between those segments. For instance, a transition in copy number is expected between two segments to either side of the start of a deletion, with the difference in segment copy number equal to the number of chromosomes harbouring the deletion event, or equivalently, the number of copies of the deletion breakpoint. A mismatch in segment and breakpoint copy number implies that at least one segment end is left disconnected (Fig. 2 d). We call these free ends telomeres, and define the transition factors of our probability model in terms of the number of telomeres t implied by the segment and breakpoint copy number. Without a breakpoint, the number of telomeres is simply the absolute difference in copy number between adjacent segments t(c,c ^{′})=c−c ^{′}. Depending on its orientation, a positive copy number for a breakpoint may explain some or all of the difference in copy number between adjacent segments. The number of telomeres at a transition coincident with a breakpoint can thus be calculated as t(c,c ^{′},b ^{′},o)=c−c ^{′}−o·b, with orientation o∈{−1,+1}. For multiple clones, t may be a more complex function of the copy number differences for each clone (see Additional file 1: Section 1.4).
Define transition factors \(f(c, c^{\prime }, b  o, \lambda) = e^{\lambda t(c, c^{\prime }, b  o)}\phantom {\dot {i}\!}\), and let k _{ n } be the index of the breakpoint interposed between segment n and n+1. Write the joint probability over the observed read counts and segment and breakpoint copy number as given by Eq. 2:
Exact inference in the ReMixT model is intractable due to additional dependencies introduced by modelling the longrange connectivity of breakpoints.
Structured variational inference
We are seeking to infer the posterior probability p(zx) of the unobserved model variables z given observed data x. The variational inference approach seeks to approximate an intractable posterior p(zx) with a more tractable family of distributions q(z), typically characterized by an increased number of parameters and fewer dependencies [19]. An optimal q(z) is computed by minimizing the KullbackLeibler (KL) divergence between p(zx) and q(z) as given by Eq. 3:
The expectation given in the final form of Eq. 3 forms a lower bound on the model evidence p(x), since D _{KL}(q(z)p(zx)) is positive and approaches zero for a perfect approximation. Importantly, the difficult problem of directly minimizing the KL divergence is equivalent to the easier problem of maximizing this evidence lower bound (ELBO). The mean field approximation assumes a distribution \(q(z) = \prod _{i} q_{i}(z_{i})\) that factorizes over single model variables. In structured variational inference, each z _{ i } is a disjoint set of model variables, allowing q to have a more complex dependency structure that better approximates the posterior [20, 21]. Independence between factors of q allows for application of a coordinate descent algorithm that iteratively maximizes the ELBO with respect to each q _{ i } using general updates given by Eq. 4:
We approximate the posterior p(C,B,h,θX,L,O,λ) using a distribution q with factorization given by Eq. 5:
Taking a variational expectation maximization (EM) approach, we specify the distributional form of q(h) and q(θ) to be the Dirac delta function, and compute point estimates for those parameters. Applying Eq. 4 to q(C) results in Eq. 6 ^{2}:
By inspection, the probability distribution q ^{∗}(C) given by Eq. 6 has a chain topology equivalent to an HMM, with an emission calculated as a function of the read count likelihood and transition matrices calculated by modifying f according to \(q_{k_{n}}(b)\) (Eqs. 7 and 8). The emission and transition terms ζ _{ n }(c _{ n }) and ζ _{ n }(c _{ n },c _{ n+1}) define the variational parameters of q(C). The sum product algorithm can be used to calculate the single and pairwise posterior marginal probabilities of q(C), denoted γ _{ n }(c) and γ _{ n }(c,c ^{′}) respectively. The posterior marginals of q(C) will appear in the updates of the other factors of q, as shown below.
Applying Eq. 4 to optimize q _{ k }(b _{ k }) results in Eq. 9:
Intuitively, the variational updates for q(C) and q _{ k }(b _{ k }) described above involve first updating the transition matrices of an HMM, weighting specific transitions that correspond to copy number changes induced by highprobability breakpoint copy number states, and then updating breakpoint copy number states according to the probabilities over adjacent segments in the HMM.
Since the entropy of a delta function is constant, optimal estimates of h and θ involve minimizing only the \(\mathbb {E}_{q} \left [ \log p(x,z) \right ]\) term of the ELBO. Read counts are independent of breakpoints given segment copy number; thus, the expectation is calculated over q(C) only (Eq. 10). Minimization is accomplished by computing derivatives with respect to the parameters and using quasiNewton methods to find a local minimum.
Realistic simulations of bulk genome sequencing
We developed a principled method of simulating rearranged genomes that fulfilled three important criteria. First, the simulated tumour genomes were required to have been produced by a known evolutionary history composed of duplication, deletion, and balanced rearrangement events applied successively to an initially nonrearranged normal genome. Second, the copy number profile of the simulated tumour genome should be reasonably similar to those of previously observed tumours. Third, the simulated data should be subject to the same biases seen in real genome sequence data.
To satisfy the first two criteria, we developed a sampling framework for generating realistic evolutionary histories based on a scoring and resampling strategy (see Additional file 1: Section 2.1). This first step produces a set of rearrangements, in addition to perclone persegment copy numbers. WGS readlevel data are generated from segment copy numbers in one of two possible ways. For segment count simulations, read counts are simulated directly from a likelihood model given simulated segment copy number. For aligned read resampling, individual reads are resampled from a very high depth source normal genome dataset based on simulated segment copy number. By using an appropriate likelihood model, segment count simulations can be used to generate read counts with a distribution that reflects the overdispersion and outliers in real data. Aligned read resampling datasets are computationally more intensive to generate, but are able to produce read count data with GC and mappability bias similar to that of the source dataset. See Additional file 1: Section 2.2 for additional details.
Breakpoint model improves inference for segment count simulations
We first sought to understand the benefit of an integrated breakpoint model using segment count simulations. We compared the ReMixT model with an equivalent breakpointnaive HMM followed by post hoc breakpoint copy number calculation. For the breakpointnaive model, we first infer segment copy number using the ReMixT model with breakpoint copy number at zero. We then use a simple greedy algorithm (see Additional file 1: Section 2.5) to perform a post hoc computation of the breakpoint copy number based on the segment copy number inferred using the HMM. As variational inference is sensitive to initialization, we also included results using the ReMixT breakpoint model with perfect initialization. We performed our evaluation on two sets of simulations, one in which we varied the proportion of the genome simulated to be subclonal, and one in which we varied the descendant clone fraction (see Additional file 1: Section 2.3 for details)^{3}.
We evaluated the breakpoint model and the HMM on the model’s ability to recover the true clonal mixture, segment copy number, and breakpoint copy number (Fig. 2). Mixture prediction was assessed by calculating the relative deviation of the predicted normal fraction and descendant clone fraction from the simulated values. Segment and breakpoint copy number prediction was assessed by calculating the proportion of segments/breakpoints for which the true clonespecific copy number was recovered by the method.
For both segment and breakpoint copy number prediction, the breakpoint model outperformed the baseline HMM. The proportion of segment copy number called correctly was significantly higher for the breakpoint model for all simulations with the exception of those simulations with a descendant clone fraction of 55% (paired t test, p value <0.05, Fig. 3 a and b). Additionally, the proportion of breakpoints with correctly predicted copy number was significantly higher for the breakpoint model for all simulations with the exception of those with the proportion of the genome subclonal set at 45% (paired t test, p value <0.05, Fig. 3 c and d). Improvement with respect to prediction of minor clone fraction was observed for descendant clone fractions 0.05 and 0.3 (paired t test, p value <0.05, Fig. 3 g). No improvement was observed with respect to normal fraction prediction, though we did observe a decrease in accuracy for descendant clone fraction 0.55 (paired t test, p value =0.03, Fig. 3 e). Perfect initialization showed improved results over our current initialization method, indicating additional room for improvement with respect to this aspect of the algorithm.
Comparison with existing copy number inference methods
We used our aligned read resampling framework to compare the performance of ReMixT to four existing methods for subclonal copy number inference: TITAN [5], CloneHD [7], Battenberg [8], and THetA2 [12, 14]. We performed our comparison on two sets of genome mixtures, one in which we varied the proportion of the genome simulated to be subclonal, and one in which we varied the descendant clone fraction. We used aligned read resampling to produce realistic simulated datasets using 200X sequencing of the NA12878 hapmap individual provided by Illumina [22]. Each tool was run with default parameters according to available instructions (see Additional file 1: Section 4 for details).
Performance of the four tools varied significantly across each measure (Fig. 3). CloneHD was unable to recover the copy number of the dominant clone with reasonable accuracy for a majority of the simulations (< 43% accurate for 50% of simulations). In general, CloneHD copy number results showed a higher mean ploidy and higher divergent proportion (proportion of the genome predicted to have clonally divergent copy number) than simulated results (average 37% higher and 44% higher respectively). However, in many instances, CloneHD was able to estimate normal fraction with reasonable accuracy (within 6.6% of simulated for 50% of the simulations). Minor clone fraction estimation was less accurate (within 28% of simulated for 50% of the simulations). Our results imply that CloneHD is prone to overfitting, producing unrealistic copy number profiles.
THetA, by contrast, produced solutions accurate with respect to mean ploidy (within 6.5% of simulated for 75% of simulations) and, to a lesser extent, divergent proportion (within 20% of simulated for only 25% of simulations). Additionally, THetA copy number predictions were more consistent in their accuracy, with the dominant copy number predicted with greater than 81% accuracy for 50% of the simulations. The normal fraction estimation error was in general higher than for the other tools (within 17% of simulated for 50% of simulations). THetA’s estimated descendant clone fractions were also less accurate than those of the other tools (within 21% of simulated for only 25% of simulations).
TITAN’s results were the most variable, with dominant copy predicted accurately for a large number of simulations (> 88% for 25% of simulations) but poorly for many other simulations (< 21% for 25% of simulations). As with CloneHD, TITAN appeared to overfit for a subset of the simulations, producing solutions for which mean ploidy and divergent proportion were higher than simulated (> 28% higher than simulated ploidy for 25% of simulations and > 66% higher than simulated divergent proportion for 50% of simulations). TITAN estimated normal fractions with low error for a majority of simulations (within 5% of simulated for 50% of simulations), though prediction of minor clone fractions was more variable (error greater than 19% of simulated for 75% of simulations).
Battenberg’s results were the most consistent of the competing tools. For the simulations with 50/50 tumour mixtures, Battenberg produced a solution at double the simulated ploidy, highlighting the unidentifiability of this particular scenario. Excluding the 50/50 tumour mixture simulations, Battenberg predicted dominant copy number within 3% for 75% of the simulations and ploidy within 4% for 75% of the simulations. Battenberg in general underestimated the divergent proportion, 13% lower than simulated for 75% of simulations. Normal fractions were also accurate, within 6% of simulated for 100% of simulations, excluding 50/50 mixtures. Battenberg does not estimate minor clone fraction and was thus excluded from such analyses.
ReMixT consistently outperformed the four competing tools on all measures. For 75% of the simulations, ReMixT was able to infer integer copy number for both clones with greater than 91% accuracy. Lower accuracy results were obtained for 50/50 tumour mixtures, primarily due to the inherent ambiguity of assigning copy numbers to specific clones for such mixtures. Normal fraction estimation was slightly biased, and was overestimated by 1.4% of simulated on average, though never by more than 2.6%. As expected, minor clone fraction estimation was less accurate for mixtures with the smallest simulated minor clone fractions, up to 50% of simulated, averaging 5%. For the remaining simulations minor clone fraction estimation error averaged 0.6% with a maximum of 8%.
Targeted single cell validation of clonespecific breakpoints
Next we sought to establish the accuracy of breakpoint copy number inference in a realistic setting using targeted single cell sequencing in a set of specially separated highgrade serous ovarian tumour samples [23]. The set of samples included two obtained from the patient’s right ovary, one from the left ovary, and one from the omentum (Fig. 5 b). Each sample was whole genome sequenced to an approximate depth of 30X.
We handselected 12 breakpoints associated with putative copy number changes for validation by targeted single cell sequencing (Fig. 4). Specifically, for each of the 12 candidate breakpoints, at least one breakend coincided with a transition in copy number in at least one sample, where copy number was inferred using an earlier version of ReMixT [23]. In addition, we selected 60 somatic and 24 germline single nucleotide changes based on their utility as clonal markers [23]. Targeted single cell sequencing was performed as previously described [23], cells were clustered into clones using the Single Cell Genotyper [24], and breakpoints were assigned to clones if they were present in at least three cells of that clone. Joint analysis of the breakpoint and single nucleotide data produced a robust estimate of the clonal genotypes with respect to the targeted breakpoints (Fig. 4 a).
Next we evaluated the ability of ReMixT to accurately determine which breakpoints were present/absent and clonal/subclonal in each sample. We calculated the F measure for present/absent and clonal/subclonal calls (Fig. 4 c). F measure values were similar to results obtained from running ReMixT on aligned read resampling simulations.
Tracking clonal expansions using clonespecific breakpoints
Several previous studies have used clonespecific SNVs to identify patterns of clonal evolution [25], infer patterns of cancer cell dissemination to metastatic sites [23, 26], and track expansion and contraction of tumour clones over time and in response to therapy [27] and in response to xenograft passaging [15]. We sought to evaluate the utility of clonespecific breakpoints predicted by ReMixT for investigating clonal evolution in successive xenograft passages. To this end, we analysed primary and xenograft tumour samples derived from a patient with breast cancer (SA501 from [15]). Our analysis focused on four samples, the primary tumour sample and three xenograft samples labelled X1A, X3A, and X3F. The relationship between these four samples and the additional two unsequenced xenograft samples X2A and X2F is shown in Fig. 5 b.
For validation of X3F clonespecific copy number changes, we used recently published single cell WGS data [28]. We inferred total integer copy number and performed phylogenetic analysis using previously described techniques [15, 28]. Three major clones were identified. Proportions of cells assigned to each clone were 0.82, 0.11, and 0.07 for clones A, B, and C respectively. Clones B and C were highly similar and formed a distinct clade; thus, for this analysis we merged clones B and C. For clone A and merged clone BC, we reconstructed clone copy number profiles by selecting the most prevalent copy number within each clone for each segment. Segments with copy number 6 or higher were removed, as specific copy number states above 5 could not be inferred using available techniques.
ReMixT analysis using default parameters estimated a clonal mixture of 0.85 for the dominant clone and 0.15 for the minor clone. Clonespecific copy numbers matched single cell copy number for 91% of the genome. Accuracy was highest for segments in lower copy number states (≤ 3 total copies). Segments with higher copy number (≥ 4 total copies) and no clonal divergence were frequently predicted as subclonal by ReMixT, evidence that ReMixT overfits some segments with higher copy number (Fig. 5 c). Additional disparity appeared to be the result of noisy segments in lower copy states predicted as subclonal.
Next we identified a set of high confidence subclonal breakpoints for analysis of clonal dynamics in the xenograft passages. We smoothed segments smaller than 100 kb and aggregated adjacent segments with the same allelespecific difference between clone copy numbers. We then removed segments with length less than 1 Mb or copy number greater than 4. Breakpoints were selected if they were predicted to be subclonal, and were immediately adjacent at each breakend to a segment with subclonal copy number from the above set of filtered high confidence segments. This technique was used to identify 17 subclonal breakpoints in one of X1, X3A, X3F, and X5 or the primary tumour sample. In X3F, the ReMixT copy number matched the single cell copy number for 84% of the 1Mb regions to either side of each breakend. For 11 of the predictions, corroboration was >92%, and for the remaining predictions, corroboration was closer to 50%, indicating a lack of corroboration on one side of each breakend. Included in the set of breakpoints were interchromosomal translocations linking subclonal segments on disparate chromosomes, indicative of clonespecific loss or gain of rearranged tumour chromosomes (Fig. 5 d and e).
Patient SA501 was previously shown to have exhibited reproducible patterns of clonal expansions across multiple replicate xenografts using a combination of targeted bulk and single cell sequencing of SNVs [15]. In particular, X3A and X3B showed similar patterns of clonal expansions for clusters of SNVs used as clonal markers. We sought to establish whether the same clonal dynamics were evident in X3F, and whether those clonal dynamics could be understood using clonalspecific breakpoints. To that end, we classified each of the high confidence subclonal breakpoints according to whether they exhibited the same expansion patterns from X1 to X3A and X1 to X3F. Of the 17 high confidence breakpoints, 6 could be classified as ascending in both X3A and X3F, 6 as descending in both X3A and X3F, with the remaining stable from X1 to either X3A or X3F (Fig. 5 a). Strikingly, we did not identify any conflicting breakpoints, those ascending in X3A and descending in X3F or vice versa.
Assembling tumour chromosomes using subclonal breakpoints
We applied ReMixT to WGS data from two tumourderived cell line samples and a matched normal sample obtained from a patient with HGSOvCa [29]. The two cell lines are derived from an ascites sample (DAH354) and a primary tumour sample (DAH355) obtained during debulking surgery. Cell line samples and matched normals were sequenced to approximately 30X and analysed with ReMixT using default parameters. Tetraploid solutions were selected based on ploidy evidence from preliminary single cell sequencing experiments for DAH355 (data not shown).
As expected of HGSOvCa, the copy number profiles of the cell line samples showed substantial evidence of genome instability. For both samples, the fraction of the genome predicted to be diploid heterozygous was insignificant, and the fraction of the genome with loss of heterozygosity was 40% and 35% for DAH354 and DAH355 respectively. Both DAH354 and DAH355 showed evidence of multiple genomically distinct clonal populations, with dominant clone fractions of 0.7 and 0.61 respectively, and fraction of the diploid genome predicted as subclonal as 14% and 32% respectively. A total of 348 somatic breakpoints were identified by deStruct [4], of which 278 were determined to be present (positive copy number) by ReMixT in one or both samples. A total of 97 breakpoints were predicted to have clonespecific copy number in one or both samples, with 17 having clonespecific copy number in both samples.
In both DAH354 and DAH355, we observed several clonespecific translocations adjacent to large segments with clonally divergent copy numbers. As with SA501, we suspected that the loss or duplication of a single tumour chromosome would result in multiple clonally divergent segments across the reference genome. We thus searched for clonally divergent segments connected by subclonal breakpoints as a method for understanding the structure of tumour chromosomes with divergent copy number across the clonal population (Fig. 6). In DAH354, we identified a tumour chromosome composed of three segments from reference chromosomes 7, 11, and 9 (Fig. 6 a), and in DAH355, we identified a tumour chromosome composed of four segments from reference chromosomes 6, 1, 3, and 15 (Fig. 6 b).
Discussion
We have demonstrated that ReMixT improves both inference and interpretation of copy number changes and genomic rearrangements. Improved accuracy was observed for prediction of clone fraction, clone specific copy number, and clone specificity of breakpoints. We show how breakpoint copy number changes can be used a markers of clonal populations, and used to track clonal population dynamics in the same way as SNVs. By linking clone specific copy number changes to breakpoints we show how targeted single cell sequencing can be used to jointly profile clonal genotypes in SNV and copy number space. Furthermore, we are able to reconstruct partial tumour chromosomes lost or gained in subpopulations of cells.
Although our method shows performance gains over other methods, further improvements are possible. The performance of our variational inference algorithm is highly dependent on the quality of the initialization. Improvement may be gained using more sophisticated or informed initialization methods, or extensions to variational inference using annealing or MCMC. Our current implementation is limited to two tumour clones, largely due to the increased computational complexity of modelling additional clones. An approximating distribution factorized per clone would solve the complexity issue within the context of structured variational inference, however based on our own experimentation, such a factorization exacerbates the initialization problem and was found to be infeasible. Thus improvements to the variational inference method may also allow for the use of a more factorized approximation, removing the limitation on the number of clones.
Conclusions
Traditionally, classes of genomic aberration have been predicted and characterized independently, with posthoc analysis to determine correlation between events in each class. However, there are clear dependencies between classes of aberrations with respect to their generation via mutational processes and their observation using genome sequencing. A number of existing methods partially leverage class dependencies[7, 30, 31], and the development of ReMixT represents a further step towards a comprehensive model of genomic aberrations in tumour populations. We anticipate further benefit may be gained from jointly modelling copy number changes, rearrangements, SNPs and SNVs, all within the context of an appropriate phylogenetic model. Future research leveraging the patterns of genome damage and the totality of somatic alterations in a cancer’s evolutionary history to elucidate its biologic and mutagenic properties will derive benefit from ReMiXT’s improved accuracy in structural alteration detection and interpretation.
Endnotes
^{1} A product of normalized conditional probabilities and a prior probability for the first segment would also be possible, though we believe integration of breakpoints into the model would be less intuitive.
^{2} Assuming uniform improper priors over h and θ, we have logp(X,C,Bh,θ,L,O,λ)= logp(X,C,B,h,θL,O,λ)+const.
^{3} We maintained a distinction between ancestral/descendant clone mixtures of x / 1−x and the reversed 1−x / x clone mixture, as results for these mixtures differ.
Change history
06 October 2017
A correction to this article has been published.
References
Rausch T, Zichner T, Schlattl A, Stütz AM, Benes V, Korbel JO. Delly: structural variant discovery by integrated pairedend and splitread analysis. Bioinformatics. 2012; 28(18):333–9.
Hormozdiari F, Alkan C, Eichler EE, Sahinalp SC. Combinatorial algorithms for structural variation detection in highthroughput sequenced genomes. Genome Res. 2009; 19(7):1270–8.
Layer RM, Chiang C, Quinlan AR, Hall IM. Lumpy: a probabilistic framework for structural variant discovery. Genome Biol. 2014; 15(6):84.
McPherson A, Shah SP, Sahinalp SC. deStruct: accurate rearrangement detection using breakpoint specific realignment. bioRxiv. 2017. https://doi.org/10.1101/117523.
Ha G, Roth A, Khattra J, Ho J, Yap D, Prentice LM, Melnyk N, McPherson A, Bashashati A, Laks E, Biele J, Ding J, Le A, Rosner J, Shumansky K, Marra MA, Gilks CB, Huntsman DG, McAlpine JN, Aparicio S, Shah SP. TITAN: inference of copy number architectures in clonal cell populations from tumor wholegenome sequence data. Genome Res. 2014; 24(11):1881–93.
Oesper L, Mahmoody A, Raphael BJ. THetA: inferring intratumor heterogeneity from highthroughput dna sequencing data. Genome Biol. 2013; 14(7):80.
Fischer A, VázquezGarcía I, Illingworth CJR, Mustonen V. Highdefinition reconstruction of clonal composition in cancer. Cell Rep. 2014; 7(5):1740–52.
NikZainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, Raine K, Jones D, Marshall J, Ramakrishna M, Shlien A, Cooke SL, Hinton J, Menzies A, Stebbings LA, Leroy C, Jia M, Rance R, Mudie LJ, Gamble SJ, Stephens PJ, McLaren S, Tarpey PS, Papaemmanuil E, Davies HR, Varela I, McBride DJ, Bignell GR, Leung K, Butler AP, Teague JW, Martin S, Jönsson G, Mariani O, Boyault S, Miron P, Fatima A, Langerød A, Aparicio SAJR, Tutt A, Sieuwerts AM, Borg Å, Thomas G, Salomon AV, Richardson AL, BørresenDale AL, Futreal PA, Stratton MR, Campbell PJ, Breast Cancer Working Group of the International Cancer Genome Consortium. The life history of 21 breast cancers. Cell. 2012; 149(5):994–1007.
Boeva V, Popova T, Bleakley K, Chiche P, Cappo J, Schleiermacher G, JanoueixLerosey I, Delattre O, Barillot E. Controlfreec: a tool for assessing copy number and allelic content using nextgeneration sequencing data. Bioinformatics. 2012; 28(3):423–5.
Mahmoody A, Kahn CL, Raphael BJ. Reconstructing genome mixtures from partial adjacencies. BMC Bioinforma. 2012; 13 Suppl 19:9.
Zerbino DR, Paten B, Hickey G, Haussler D. An algebraic framework to sample the rearrangement histories of a cancer metagenome with double cut and join, duplication and deletion events. arXiv. 2013. arXiv:1303.5569v1.
Oesper L, Ritz A, Aerni SJ, Drebin R, Raphael BJ. Reconstructing cancer genomes from pairedend sequencing data. BMC Bioinformatics. 2012; 13 Suppl 6:10.
Li Y, Zhou S, Schwartz DC, Ma J. Allelespecific quantification of structural variations in cancer genomes. Cell Syst. 2016; 3(1):21–34.
Oesper L, Satas G, Raphael BJ. Quantifying tumor heterogeneity in wholegenome and wholeexome sequencing data. Bioinformatics. 2014; 30(24):3532–40. doi:10.1093/bioinformatics/btu651.
Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, Gelmon K, Chia S, Mar C, Wan A, Laks E, Biele J, Shumansky K, Rosner J, McPherson A, Nielsen C, Roth AJL, Lefebvre C, Bashashati A, de Souza C, Siu C, Aniba R, Brimhall J, Oloumi A, Osako T, Bruna A, Sandoval JL, Algara T, Greenwood W, Leung K, Cheng H, Xue H, Wang Y, Lin D, Mungall AJ, Moore R, Zhao Y, Lorette J, Nguyen L, Huntsman D, Eaves CJ, Hansen C, Marra MA, Caldas C, Shah SP, Aparicio S. Dynamics of genomic clones in breast cancer patient xenografts at singlecell resolution. Nature. 2015; 518(7539):422–6.
Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. Nat Methods. 2012; 9(2):179–81.
Benjamini Y, Speed TP. Summarizing and correcting the GC content bias in highthroughput sequencing. Nucleic Acids Res. 2012; 40(10):72.
Medvedev P, Fiume M, Dzamba M, Smith T, Brudno M. Detecting copy number variation with mated short reads. Genome Res. 2010; 20(11):1613–22.
Blei DM, Kucukelbir A, McAuliffe JD. Variational inference: A review for statisticians. 2016. arXiv preprint arXiv:1601.00670.
Saul LK, Jordan MI. Exploiting tractable substructures in intractable networks. Adv Neural Inform Process Syst. 1996;486–92.
Ghahramani Z, Jordan MI, Smyth P. Factorial hidden Markov models. Mach Learn. 1997; 29(23):245–73.
Eberle MA, Fritzilas E, Krusche P, Källberg M, Moore BL, Bekritsky MA, Iqbal Z, Chuang HY, Humphray SJ, Halpert AL, et al. A reference dataset of 5.4 million human variants validated by genetic inheritance from sequencing a threegeneration 17member pedigree. bioRxiv. 2016;055541.
McPherson A, Roth A, Laks E, Masud T, Bashashati A, Zhang AW, Ha G, Biele J, Yap D, Wan A, Prentice LM, Khattra J, Smith MA, Nielsen CB, Mullaly SC, Kalloger S, Karnezis A, Shumansky K, Siu C, Rosner J, Chan HL, Ho J, Melnyk N, Senz J, Yang W, Moore R, Mungall AJ, Marra MA, BouchardCôté A, Gilks CB, Huntsman DG, McAlpine JN, Aparicio S, Shah SP. Divergent modes of clonal spread and intraperitoneal mixing in highgrade serous ovarian cancer. Nat Genet. 2016; 48(7):758–67.
Roth A, McPherson A, Laks E, Biele J, Yap D, Wan A, Smith MA, Nielsen CB, McAlpine JN, Aparicio S, BouchardCôté A, Shah SP. Clonal genotype and population structure inference from singlecell tumor sequencing. Nat Methods. 2016; 13(7):573–6.
Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, HeraviMoussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, Griffith M, Moradian A, Cheng S. W. G, Morin GB, Watson P, Gelmon K, Chia S, Chin SF, Curtis C, Rueda OM, Pharoah PD, Damaraju S, Mackey J, Hoon K, Harkins T, Tadigotla V, Sigaroudinia M, Gascard P, Tlsty T, Costello JF, Meyer IM, Eaves CJ, Wasserman WW, Jones S, Huntsman D, Hirst M, Caldas C, Marra MA, Aparicio S. The clonal and mutational evolution spectrum of primary triplenegative breast cancers. Nature. 2012; 486(7403):395–9.
Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio HML, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O’Meara S, Dawson KJ, Isaacs W, EmmertBuck MR, Nykter M, Foster C, KoteJarai Z, Easton D, Whitaker HC, ICGC Prostate UK Group, Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015; 520(7547):353–7.
Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, McMichael JF, Wallis JW, Lu C, Shen D, Harris CC, Dooling DJ, Fulton RS, Fulton LL, Chen K, Schmidt H, KalickiVeizer J, Magrini VJ, Cook L, McGrath SD, Vickery TL, Wendl MC, Heath S, Watson MA, Link DC, Tomasson MH, Shannon WD, Payton JE, Kulkarni S, Westervelt P, Walter MJ, Graubert TA, Mardis ER, Wilson RK, DiPersio JF. Clonal evolution in relapsed acute myeloid leukaemia revealed by wholegenome sequencing. Nature. 2012; 481(7382):506–10.
Zahn H, Steif A, Laks E, Eirew P, VanInsberghe M, Shah SP, Aparicio S, Hansen CL. Scalable wholegenome singlecell library preparation without preamplification. Nat Methods. 2017; 14(2):167–73.
Létourneau IJ, Quinn MCJ, Wang LL, Portelance L, Caceres KY, Cyr L, Delvoye N, Meunier L, de Ladurantaye M, Shen Z, Arcand SL, Tonin PN, Provencher DM, MesMasson AM. Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer. BMC Cancer. 2012; 12:379.
Greenman CD, Pleasance ED, Newman S, Yang F, Fu B, NikZainal S, Jones D, Lau KW, Carter N, Edwards PAW, Futreal PA, Stratton MR, Campbell PJ. Estimation of rearrangement phylogeny for cancer genomes. Genome Res. 2012; 22(2):346–61.
Deshwar AG, Vembu S, Yung CK, Jang GH, Stein L, Morris Q. PhyloWGS: reconstructing subclonal composition and evolution from wholegenome sequencing of tumours. Genome Biol. 2015; 16:35.
Acknowledgements
We thank Dr. AnneMarie MesMasson, CHUM Research Centre (CRCHUM), Montreal, Canada for providing the highgrade serous ovarian cancer cell lines.
Funding
This work was supported by a Discovery Frontiers project grant, The Cancer Genome Collaboratory, jointly sponsored by the Natural Sciences and Engineering Research Council (NSERC), Genome Canada (GC), the Canadian Institutes of Health Research (CIHR), and the Canada Foundation for Innovation (CFI) to SPS and SCS. In addition, we acknowledge generous longterm funding support from the BC Cancer Foundation. The SPS and SA groups receive operating funds from the Canadian Breast Cancer Foundation, the Canadian Cancer Society Research Institute (impact grant 701584 to SA and SPS), the Terry Fox Research Institute (Program Project Grants program on forme fruste tumours), the CIHR (grant MOP115170 to SA and SPS), and the CIHR Foundation (grant FDN143246 to SPS). SPS and SA are supported by Canada Research Chairs. SPS is a Michael Smith Foundation for Health Research scholar. Additional funding is provided by NIH GM108348 and by the Indiana University Precision Health Grand Challenge Initiative to SCS.
Availability of data and materials
ReMixT is written in Python and C++. Source code is available at http://bitbucket.org/dranew/remixt, released under the MIT license. The version of ReMixT used for this manuscript has been published on http://zenodo.org with doi: http://dx.doi.org/10.5281/zenodo.819479.
Highgrade serous ovarian cancer
We used previously published data [23] available from the European Genomephenome Archive (http://www.ebi.ac.uk/ega/) under accession number [EGA:S00001000547].
Breast cancer
We used previously published data [28] available from the European Genomephenome Archive (http://www.ebi.ac.uk/ega/) under accession number [EGA:S00001002170].
Author information
Authors and Affiliations
Contributions
AM developed and implemented the algorithm, performed the analysis, and wrote the manuscript. AS analyzed the SA501 single cell data. PE was responsible for development of the xenograft models. SPS contributed to the manuscript text. AR, GH, CC, CD, AB, SCS, and SA contributed ideas during development of the model and analysis of the results. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Highgrade serous ovarian cancer.
Ethical approval was obtained from the University of British Columbia (UBC) Research Ethics Board (H0801411 NGS Huntsman). Women undergoing debulking surgery (primary or recurrent) for carcinoma of ovarian, peritoneal, and/or fallopian tube origin were approached for informed consent for the banking of tumour tissue. All experimental methods comply with the Helsinki Declaration.
Breast cancer
Anonymized tumour tissue from women aged 26–82 undergoing surgery or diagnostic core biopsy was collected with informed consent, according to procedures approved by the UBC Research Ethics Board (H0600289 Breast Tumour Tissue Repository and H1301125 Breast Xenograft Aparicio). All experimental methods comply with the Helsinki Declaration.
Patientderived xenografts
Female NOD/SCID interleukin2 receptor gamma null (NSG) and NOD Rag1 null interleukin2 receptor gamma null (NRG) mice were bred and housed at the Animal Resource Centre at the British Columbia Cancer Research Centre and the Biological Resource Unit at the Cancer Research UK Cambridge Research Institute. Surgery was carried out on mice between the ages of 5–10 weeks. All experimental procedures were approved by the University of British Columbia Animal Care Committee and the University of Cambridge Animal Welfare and Ethical Review Committee.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Additional information
A correction to this article is available online at https://doi.org/10.1186/s1305901713277.
Additional file
Additional file 1
Supplementary methods, supplementary analyses, and additional experimental results. (PDF 35000 kb)
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
McPherson, A., Roth, A., Ha, G. et al. ReMixT: clonespecific genomic structure estimation in cancer. Genome Biol 18, 140 (2017). https://doi.org/10.1186/s1305901712672
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s1305901712672